Clinical Design and Current Status

The NCT05636020 study, sponsored by Indiana University, is a single-center interventional study evaluating ICARE, which aims to improve emotional recognition and empathic behavior in patients with traumatic brain injury (TBI). ICARE is a 12-session remote rehabilitation (TeleRehabilitation) program that trains emotional cue interpretation and empathic responses; it is not a drug or molecular-targeted therapy. Caregivers participate in the empathy training sessions. This is a clinical trial exploring feasibility, acceptability, and preliminary efficacy, rather than following the traditional Phase 1/2/3 drug development pathway. The target enrollment is 40 patients, and the study is currently active but not recruiting. It began in March 2023, with primary completion and study end dates projected for October 2026.

Signals from Initial Evidence

A prior pre- and post-comparison study showed that 7 out of 8 pairs of mild to severe TBI patients and caregivers completed the 12-session program, resulting in an 88% completion rate, with no study-related adverse events. The patients' total emotional recognition scores improved by an average of 4.57 points, and self-reported social interaction improved by an average of 5.70 points, while caregiver ratings increased by 7.80 points. The quality of the relationship, as rated by the patients, also improved from 6.57 to 8.29 on a 10-point scale. However, this is based on small, single-arm data, so the results of the NCT05636020 study will determine the effect size and reproducibility. This study is clinically significant because it aims to demonstrate that the effects extend beyond simple cognitive test improvements to interpersonal relationships within the home.

Competitive Landscape and Unmet Need

The current standard of care for TBI rehabilitation involves combining physical therapy, occupational therapy, speech therapy, neuropsychological therapy, and cognitive rehabilitation for each patient. There are no approved drugs that directly target emotional recognition and empathy to form a treatment axis. Online SoCoBo, a competing intervention, improved facial emotion recognition and self-reported empathy in a randomized study of 64 TBI patients, but did not show improvement in theory of mind or social problem-solving. RehaCom is a commercially available computer-based cognitive rehabilitation program, but differs from ICARE in its specific focus on social cognition. T-ScEmo and TREAT are also non-pharmacological programs that target social cognition, emotion regulation, and emotional recognition deficits. The literature indicates that 13-39% of moderate to severe TBI patients experience emotional perception deficits, and up to 70% report low empathy, which supports the significant unmet need in this area.

Market Potential and Regulatory Considerations

The global medical rehabilitation services market is estimated at USD 290.74 billion in 2025, providing a broad commercial base for standardized programs that can be delivered remotely. However, ICARE is a researcher-driven behavioral intervention from Indiana University and is not a branded drug, generic ingredient, or targeted molecule; it is not currently a marketed product. Therefore, clinical efficacy, therapist training, insurance reimbursement, and real-world applicability are key value drivers, rather than FDA, EMA, or PMDA approval or advisory committee (AdComm) review. After the study is completed in 2026, evidence of efficacy compared to a control group and transfer to daily life will be needed to support licensing to hospitals and rehabilitation centers or partnerships with digital therapeutic platforms.